Format:
Online-Ressource
,
v.: digital
Edition:
Online-Ausg. Springer eBook Collection. Biomedical and Life Sciences Electronic reproduction; Available via World Wide Web
ISBN:
9780387690629
Content:
Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies.
Content:
Each chapter will focus on the known molecular characteristics of specific childhood cancers, focusing on how the molecular 'drivers' can be exploited from a therapeutic standpoint with currently available targeted agents. Where applicable, integration of targeted therapies with conventional cytotoxic agents will be considered. This volume will provide a comprehensive summary of molecular characteristics of childhood cancers, and how the changes involved in transformation provide us with opportunities for developing relatively less toxic, but curative, therapies
Note:
Includes bibliographical references and index
,
The Emerging Era of Targeted Therapy in Childhood Acute Lymphoblastic Leukemia; The BCR/ABL Tyrosine Kinase and Ph+ ALL; The FLT-3 Pathway in MLL Rearranged Infant ALL; The Notch Pathway in T-ALL; Monoclonal Antibodies in the Treatment of ALL; Cancer Stem Cells in ALL; Summary; References; Molecular Targeted Therapies in T-CellAcute Lymphoblastic Leukemia; Introduction; Oncogenic Transcription Factors; NOTCH1; The NOTCH1 Pathway; Strategies for NOTCH1 Inhibition; Resistance to NOTCH1 Inhibitors and Therapeutic Strategies to Overcome Resistance; PTEN, PI3K-AKT, and mTOR; Tyrosine Kinase Genes
,
RASConclusions; References; Molecularly Targeted Therapy for Infant ALL; FLT3 Tyrosine Kinase Inhibition; Targeting Anti-apoptotic BCL-2 Family Members; Targeting MLL Fusion Transcripts; PFWT Targeting of MLL Partner Protein Interactions; Targeting Glycogen Synthase Kinase 3; HSP90 as a Potential Therapeutic Target; Epigenetic Strategies; mTOR Inhibition; Targeting CD33 Cell Surface Antigen; Conclusions; References; Targeted Therapeutic Approaches for AML; Introduction; Mechanisms of Leukemogenesis: Implications for Targeted Therapy Development
,
Refining the Definition and Relevance of Targeted TherapyDevelopment of Targeted Therapies for AML; Specific Examples of Targeting AML; Targeting Pathways that Alter Leukemia Cell Proliferation and Survival; Tyrosine Kinases; Inhibition of Signaling Pathways Downstream of TK Receptors; Drug Resistance Mechanisms and Leukemic Cell Survival; Epigenetic and Chromatin Remodeling-Directed Targets; Targeted Immunotherapy and Immunostimulatory Therapy; Future Challenges; References; Acute Promyelocytic Leukaemia; Introduction; Demographic Features; Pathogenesis of APL; Diagnosis of APL
,
Treatment of APLInduction Therapy; Complications of Induction Therapy; Consolidation Therapy; Maintenance Treatment; Molecular Monitoring in APL; MRD Detection Is an Independent Predictor of Outcome in APL; Real-Time Quantitative RT-PCR Assays Enhance MRD Detection in APL; Anthracycline Cumulative Dose and Cardiotoxicity; Stem Cell Transplantation; Arsenic Trioxide; What to Do When Treatment Fails?; Extramedullary Relapse; New Drugs; Conclusions; References; Down Syndrome and Acute Myeloid Leukemia: An Unique Genetic Sensitivity to Chemotherapy; Introduction
,
Chemotherapy Sensitivity and Down SyndromeThe Role of Chromosome 21-Localized Genes and Chemotherapy Sensitivity in Down Syndrome AMkL; Relationship Between GATA1 and Chemotherapy Drug Sensitivities; Differential Gene Expression Studies and Down Syndrome AMkL; Future Challenges; Conclusion; References; Targeting RAS Signaling Pathways in Juvenile Myelomonocytic Leukemia (JMML); GM-CSF and Deregulated RAS Signaling in Pathogenesis of JMML; Mouse Models; Targeted Therapeutics; RAF/MEK/ERK; PI3K/AKT/mTOR; PTPN11/SHP-2; JAK2-STAT5; Conclusion; References
,
Chronic Myeloid Leukemia: Pathophysiology and Therapeutics
,
Electronic reproduction; Available via World Wide Web
Additional Edition:
ISBN 9780387690605
Language:
English
DOI:
10.1007/978-0-387-69062-9
URL:
Volltext
(lizenzpflichtig)
